You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
NEW YORK (360Dx) – Fujirebio today announced a deal with Janssen Pharmaceutical to develop and commercialize a test for use with the drug maker's investigational oral BACE inhibitor, atabecestat, for Alzheimer's disease.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?Login Now.
Don't have a 360Dx or GenomeWeb account?Register for Free.